

DAFTAR PUSTAKA

1. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. *Circulation*. 2003;1448-1453.
2. Sugondo S. *Obesitas*. In: Sudoyo AW. Buku ajar ilmu penyakit dalam. 6th ed. Jakarta: Interna Publishing. 2014;2559-68.
3. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol*. 2019;15(5):288-298.
4. WHO. Overweight and obesity [Internet]. 2016. Available from: https://www.who.int/gho/ncd/risk_factors/overweight_text/en/
5. Kementerian Kesehatan. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *Ris Kesehat Dasar* 2018. 2018;95.
6. Aras Ş, Üstünsoy S, Armutçu F. Indices of central and peripheral obesity; Anthropometric measurements and laboratory parameters of metabolic syndrome and thyroid function. *Balkan Med J*. 2015;32(4):414-420.
7. Castro AVB, Kolka CM, Kim SP, et al. Obesity, insulin resistance and comorbidities – Mechanisms of association. *Arq Bras Endocrinol Metab*. 2015;58(6):600-609.
8. Hayashi T, Boyko EJ, McNeely MJ, et al. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. *Diabetes*. 2008;57(5):1269-1275.
9. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart

- Study. *Obesity*. 2010;18(11):2191-2198.
10. Goldani H, Adami FS, Antunes MT, et al. Applicability of the visceral adiposity index (VAI) in the prediction of the components of the metabolic syndrome in elderly. *Nutr Hosp*. 2015;32(4):1609-1615.
 11. Wu J, Gong L, Li Q, et al. A novel visceral adiposity index for prediction of type 2 diabetes and pre-diabetes in Chinese adults: a 5-year prospective study. *Sci Rep*. 2017;7(1):1-9.
 12. Zhang M, Hu T, Zhang S, et al. Associations of different adipose tissue depots with insulin resistance : a systematic review and meta-analysis of observational studies. *Sci Rep*. 2015;(8):1-6.
 13. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index : a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care*. 2010;33(4):920-922.
 14. Zhang M, Zheng L, Li P, et al. 4-year trajectory of visceral adiposity index in the development of type 2 diabetes: A prospective cohort study. *Ann Nutr Metab*. 2016;69(2):142-149.
 15. Ji B, Qu H, Wang H, et al. Association between the visceral adiposity index and homeostatic model assessment of insulin resistance in participants with normal waist circumference. *Angiology*. 2017;68(8):716-721.
 16. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007;116(1):39-48.
 17. Bermudez V, Salazar J, Martínez MS, et al. Prevalence and associated factors

- of insulin resistance in adults from Maracaibo City, Venezuela.*Adv Prev Med.* 2016;2016:1-13.
18. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance.*Am J Physiol Endocrinol Metab.* 2008;295(5):1009-1017.
 19. Gutch M, Kumar S, Razi SM, et al. Assessment of insulin sensitivity/resistance.*Indian J Endocrinol Metab.* 2015;19(1):160-164.
 20. Lee JM, Okumura MJ, Davis MM, et al. Prevalence and determinants of insulin resistance among U.S. adolescents.*Diabetes Care.* 2006;29(11):2427-2432.
 21. Rogero Blanco ME, Albañil Ballesteros MR, Sánchez Martín M, et al. Prevalence of insulin resistance in a young adult population. Relationship with weight status.*Endocrinol y Nutr (English Ed.* 2012;59(2):98-104.
 22. Würtz P, Mäkinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults.*Diabetes.* 2012;61(6):1372-1380.
 23. Stępień M, Stępień A, Wlazeł RN, et al. Predictors of insulin resistance in patients with obesity: A pilot study.*Angiology.* 2014;65(1):22-30.
 24. Borruel S, Moltó JF, Alpañés M, et al. Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index.*PLoS One.* 2014;9(12):1-17.
 25. Amato MC, Giordano C. Visceral adiposity index : an indicator of adipose tissue Dysfunction.*Int J Endocrinol.* 2014;(4):1-7.
 26. Chávez-castillo M, Torres W, Nú V, et al. Optimal cutoff for visceral

- adiposity index in a Venezuelan population : Maracaibo city metabolic syndrome prevalence study.*Rev Argent Endocrinol Metab.* 2017;4(4):176-183.
27. Wang Y, He S, He J, et al. Predictive value of visceral adiposity index for type 2 diabetes mellitus: A 15-year prospective cohort study.*Herz.* 2015;40(9):277-281.
 28. Amato MC, Giordano C, Pitrone M, et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population.*Lipids Health Dis.* 2011;183(10):1-8
 29. Baveicy K, Mostafaei S, et al. Predicting metabolic syndrome by visceral adiposity index , body roundness index and a body shape index in adults : a cross-sectional study from the Iranian RaNCD cohort data.*Diabetes Metabolic Syndrome and Obesity : Targets and Therapy.* 2020:879-887.
 30. Cardona-alvarado MI, Lopez-moreno G, Aguilar-zavala H, et al. Relationship of visceral adiposity index with the metabolic phenotype and cardiovascular markers in non-diabetic subjects study participants.*Health Sci J.* 2018;12(5):1-8.
 31. Amato MC, Pizzolanti G, Torregrossa V, et al. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes.*PLoS One.* 2014;9(3):1-9.
 32. Kouli G, Panagiotakos DB, Kyrou I, et al. Visceral adiposity index and 10-years cardiovascular disease incidence : the ATTICA Study.*Nutr Metab*

Cardiovasc Dis. 2017;(17):1-31.

33. Wilcox G. Insulin and insulin Resistance. *Clin Biochem Rev.* 2005;26(5):19-39.
34. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity?. *Curr Opin Endocrinol Diabetes Obes.* 2014;19(2):81-87.
35. Donohoe C, Doyle S, Reynolds J. Visceral adiposity , insulin resistance and cancer risk. *Diabetol Metab Syndr.* 2011;3(12):1-13.
36. Parveen S, Haq T, Nahar N, et al. Association of visceral adiposity index with insulin resistance in adults with diabetes mellitus. *IMC J Med Sci.* 2020;14(1):1-8.
37. Kurniawan LB, Adnan E, Mulyono B. Insulin resistance and testosterone level in Indonesian young adult males. *Rom J Intern Med.* 2020;58(2):93-98.
38. Kabir M, Stefanovski D, Hsu I, et al. Large size cells in visceral adipose depot predict insulin resistance in the Canine model. *Obesity (Silver Spring).* 2011;19(11):2121-2129.
39. Borel AL, Nazare JA, Smith J, et al. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: Contribution of abdominal adiposity. *Metabolism.* 2012;61(2):262-272.
40. Mazzuca E, Battaglia S, Marrone O, et al. Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. *J Sleep Res.* 2014;23(1):13-21.
41. Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral

- adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance.*Cardiovasc Diabetol.*2014;13(1):1-10.
42. Stepanek L, Horacova D CL. Can visceral adiposity index serve as a simple tool for identifying individuals with insulin resistance in daily clinical practice?.*Medicina.* 2019;545(55):1-10.
43. Jabłonowska-lietz B, Wrzosek M, Włodarczyk M, et al. New indexes of body fat distribution , visceral adiposity index , body adiposity index , waist-to-height ratio , and metabolic disturbances in the obese.*Kardiol Pol.* 2017;75(11):1185-1191.
44. Pekgor S, Duran C, Berberoglu U, et al. The role of visceral adiposity index levels and insulin resistance in overweight and obese patients.*Metab Syndr.* 2019;17(5):296-302.
45. Juneja A, Dwivedi S, Srivastava DK, et al. Insulin resistance in young obese subjects and its relation to smoking (A Pilot Study).*Indian J Clin Biochem.* 2017;32(1):99-102.
46. Liberty IA, Roflin E, Aziz M, et al. Cut-off point optimal visceral adiposity index dan lipid accumulation product sebagai marker potensial pada prediabetes.*UNSRI Press.*2020;0(0):1-75.
47. Ikeda Y, Suehiro T, Nakamura T, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment.*Endocr J.* 2001;48(1):81-86.
48. Purnamasari D, Soegondo S, Oemardi M, et al. Insulin resistance profile among siblings of type 2 diabetes mellitus (preliminary study).*Acta Med*

Indones. 2010;42(4):204-208.

49. Coombe AH, Hayat MJ, Faulkner MS, et al. Preliminary evidence of insulin resistance in young adults with impaired sleep.*J Am Coll Heal.* 2020;0:1-7.
50. Du T, Sun X, Huo R, Yu X. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: The China Health and Nutrition Survey 2009.*Int J Obes.* 2014;38(6):840-847.



REKOMENDASI PERSETUJUAN ETIK

Nomor : 843/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 30 Desember 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20110620	No Sponsor Protokol	
Peneliti Utama	dr. Laily Ridawati	Sponsor	
Judul Peneliti	KORELASI NILAI VISCERAL ADIPOSITY INDEX (VAI) DENGAN NILAI HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE (HOMAIR) PADA POPULASI MUDA NON DIABETES.		
No Versi Protokol	1	Tanggal Versi	3 November 2020
No Versi PSP	1	Tanggal Versi	3 November 2020
Tempat Penelitian	Mahasiswa PPDS Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 Desember 2020 sampai 30 Desember 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan